NEOPROBE : 3rd Quarter Business Update Conference Call Invitation

11/08/2010| 12:10pm US/Eastern

Recommend:

0

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today confirmed that it would report its financial results for the third quarter of 2010 on Wednesday, November 10, 2010 before the opening of the financial markets. The announcement will be followed by a business update conference call with the investment community scheduled for later that afternoon on Wednesday, November 10, 2010 at 4:30 PM ET. On the call Neoprobe's President and CEO, David Bupp, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Frederick Cope, and Senior Vice President and CFO, Brent Larson, will provide a business update, review results for the third quarter of 2010 and discuss recent corporate events. The conference call can be accessed as follows:

About Neoprobe Corporation

Neoprobe Corporation (OTCBB: NEOP) is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe^® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek^® and RIGScan^?. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com.

Neoprobe Corporation
Brent Larson, 614-822-2330
Sr. VP & CFO
or
Makovsky + Company
Gene Marbach, 212-508-9645

0